RxDoctor Payments Data

Jason Rothman, MD

Urology · Durham, NCNPI 1730329699

Payments from drug & device makers

$14,719in general payments, 2019–2025

Across 617 payments — averaging $23.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$2K
  • Johnson & Johnson$2K
  • Verathon Inc.$1K
  • Astellas Pharma US Inc$977
  • Sumitomo Pharma America, Inc.$929
  • Teleflex LLC$767
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$1,3509%
  • Travel & lodging$3402%
  • Food & beverage$12,52285%
  • Education$5073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,719 in reported general payments places this provider in the 85th percentile of 434 urology providers in North Carolina.

See all urology providers in North Carolina

Medicare billing

Part B allowed, 2024
$285,062
Medicare patients
666
Services billed
6,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide30$424,761
MyrbetriqMirabegron140$119,059
OrgovyxRelugolix27$69,646
GemtesaVibegron58$39,418
Mirabegron ErMirabegron13$11,353
Tamsulosin Hcl666$10,553
XyostedTestosterone Enanthate11$10,126
Potassium Citrate ErPotassium Citrate40$5,775
Finasteride435$5,583
Alfuzosin Hcl ErAlfuzosin Hcl140$3,023
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst59$2,106
Solifenacin Succinate73$1,992
Dutasteride62$1,717
Tolterodine Tartrate ErTolterodine Tartrate18$1,675
NitrofurantoinNitrofurantoin Macrocrystal65$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,663$424,76130 claims
Astellas Pharma US IncMyrbetriq$977$119,059140 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$929$109,06385 claims
Antares Pharma, Inc.Xyosted$224$10,12611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 434 urology providers in North Carolina.

Other urology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →